Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

Lupkynis has been approved in Japan to treat lupus nephritis, when given alongside the immunosuppressant mycophenolate ...

Mycophenolate mofetil (MMF), originally used in transplantation, exerts its immunosuppressive effects through the inhibition of T- and B-lymphocyte proliferation. Its efficacy in SLE has been ...

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...

Aurinia Pharmaceuticals said Japanese regulators have approved its drug voclosporin in a combination treatment for lupus. The company said Tuesday that the Japanese Ministry of Health, Labour, and ...

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...

Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to ...

Roche announces positive results from phase III study of Gazyva/Gazyvaro in people with lupus nephritis: Basel Friday, September 27, 2024, 12:00 Hrs [IST] Roche announced positive ...

Roche (RHHBY) announced that the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in patients with active lupus nephritis ...

Lupkynis is used in adults to treat lupus nephritis ... medications that suppress your immune system, including mycophenolate mofetil and corticosteroids. This article describes the dosage ...

ROCKVILLE, Md. & EDMONTON, Alberta-- ( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...